Regeneron Pharmaceuticals (REGN): $4.68 million was the positive money flow into the stock on Thursday and the up/down ratio of ticks was also in favor of the bulls at 1.15. The value of trades done on upticks was $35.42 million, whereas, trades done on downticks were valued at $30.74 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $0.1 million worth stocks on upticks, which is a bullish indication. The money flow in block trades was $0.1 million. Regeneron Pharmaceuticals (REGN) fell $0.02 traded at $364.48, a change of -0.01% over the previous day. The stock is -3.67% for the week.
The stock has recorded a 20-day Moving Average of 2.15% and the 50-Day Moving Average is 2.32%. Shares have dropped -29.93% from its 1 Year high price. On Aug 4, 2015, the shares registered one year high at $605.93 and the one year low was seen on Jun 27, 2016. The 50-Day Moving Average price is $372.88 and the 200 Day Moving Average price is recorded at $402.34.
Regeneron Pharmaceuticals (NASDAQ:REGN): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $367.02 and $360.06 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $367.02. The buying momentum continued till the end and the stock did not give up its gains. It closed at $365.27, notching a gain of 0.21% for the day. The total traded volume was 743,864 . The stock had closed at $364.50 on the previous day.
In an insider trading activity, Ryan Arthur F, director of Regeneron Pharmaceuticals Inc, unloaded 1,000 shares at an average price of $396.64 on May 24, 2016. The total amount of the transaction was worth $396,640, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis (RA), asthma and atopic dermatitis. The Companys marketed products include EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.